Don't know if you saw this in the 10-K, but the reason that CANV said it's 1Q - 3Q filings couldn't be counted-on was probably because it's now saying that the audited cost of the Phytosphere deal was $8,020,000 (page F-12).
The 10-K also doesn't even mention the $4.50 - $6.00 collar they put on the shares anymore.
Once the $950,000 in cash they paid is subtracted, they value the 5,825,000 shares given to MJNA and HDDC at $7,070,000, which works out to $1.21/share (though they don't mention this number). And that's probably what the deal was actually worth.
I've been writing for most of the past year that the $35M price and the quarterly installments were designed to pump-up the income numbers for Phytosphere's seller, Medical Marijuana, Inc., and the drastic revision to the cost of the deal seems to indicate that the original $35M price was dramatically overstated.
What's really surprising to me is that CANV doesn't even mention the $35M value of the deal in the 10-K, though that value was mentioned in the 10-Qs for Q1 - Q3 of 2013.
This change is probably why CannaVest is having to revise their 10-Qs for 2013, but unfortunately for CANV, the announcement has attracted the attention of the Rosen Law Firm, which issued a PR on Friday evening announcing an investigation into CANV:
If they were trying to do a favor to Medical Marijuana, Inc by structuring the deal the way they did, it appears the old proverb, No good deed goes unpunished may apply here.
News 
Market Data 
Discover 
AI
